Financing channel feed – Endpoints News

Financing channel feed

Kezar and Xeris file for IPOs, joining May's march to the public markets

8 years ago

Magenta Therapeutics unveils plans to raise $100M in IPO weeks after a crossover round

8 years ago

Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug

8 years ago

Aptinyx looks to bring its NMDA pipeline to Nasdaq, filing for an $80 million IPO

8 years ago

Versant backs new approach to gamma delta T cells, co-leads Lava's $18.9M round

8 years ago

Fighting for a place in the ulcerative colitis market, Sublimity raises $64M for an alternative drug to anti-TNF

8 years ago

Grail hauls in monster $300M round from Chinese investors amid rumors about Hong Kong IPO

8 years ago

Bay Area startup Rain Therapeutics nabs $18M Series A to target lung cancer niche

8 years ago

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead

8 years ago

Tel Aviv VC fund aMoon gets $250M from Credit Suisse, emerges as top player in Israel

8 years ago

His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor

8 years ago

EIP Pharma flies into a high-risk PhIIb Alzheimer’s study fueled with $20.5M from billionaire Len Blavatnik’s Access Industries

8 years ago

Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials

8 years ago

High profile biotech investor Beth Seidenberg is exiting Kleiner Perkins and starting her own fund — report

8 years ago

Medicxi, RA Capital join $30M round for Dutch biotech's late-stage transplantation med

8 years ago

Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program

8 years ago

Third Rock, GV back Broad spinout Celsius in bid to develop precision meds for autoimmune disease

8 years ago

Cambridge spinout CellCentric gets $26M for single-asset epigenetics approach to prostate cancer

8 years ago

Waksal's gene therapy spinoff MeiraGTx says it’s time to fly with an $86M IPO

8 years ago

Targeting the tricky PI3K pathway in cancer, MEI gets $75M to push program through registration study

8 years ago

CRISPR trailblazers Zhang, Liu and Joung join forces to launch Beam with $87M and cutting-edge gene-editing tech

8 years ago

China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors

8 years ago

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback

8 years ago

Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A

8 years ago

First page Previous page 127 128 129130131 132 133 Next page Last page